Abstract
The significance of thyroxine (T4) uptake from serum in the assessment of thyroid status was evaluated, using human hepatoma (Hep G2) cells, in 30 euthyroid subjects, 6 hypothyroid and 19 hyperthyroid patients, and in 23 athyreotic cancer patients under T4 suppressive therapy. Cellular thyroxine (CT4) was determined according to Sarne and Refetoff, J. Clin. Endocrinol. Metab. 61: 1046, 1985. CT4 averaged 9.9 ± 2.8 pg/well (mean ± SD, range 5.7–15.3) in euthyroid subjects, 1.5 ± 1.0 pg/well (range 0.05–4.2) in hypothyroid patients, 40.5 ± 18.8 pg/well (range 18.3 ± 104.7) in hyperthyroid patients, and 23.7 ± 7.2 pg/well (range 14.2–40.2) in T4-treated patients. In eu-, hypo- and hyperthyroid patients, a significant correlation was observed between CT4 and free T4 index (FT4I), free T4 (FT4) or Sex Hormone Binding Globulin (SHBG) values. In T4-treated patients, CT4 values were correlated with FT4I values, but not with FT4 or SHBG levels. All T4-treated patients with elevated SHBG levels had elevated FT4, FT4I and CT4 values. In contrast, of the 16 T4-treated subjects with normal serum SHBG concentrations, all but one had normal FT3, 3 (19%) had elevated FT4, 10 (62%) elevated FT4I and 13 (81%) elevated CT4, but all (100%) had undetectable TSH levels. Thus, considering serum SHBG concentrations as a parameter of hepatic tissue response to thyroid hormone, CT4 values, at least in T4-treated patients, do not accurately reflect the liver responsiveness to thyroid hormone action.
Similar content being viewed by others
References
Kahn A. Serum thyroxine levels in patients receiving L-thyroxine suppression or replacement therapy. Can. Med. Assoc. J. 109: 279, 1973.
Murchison L.E., Chesters M.I., Bewsher P.D. Serum thyroid hormone levels in patients on thyroxine replacement therapy. Horm. Metab. Res. 8: 324, 1976.
Sawin C.T., Hershman J.M., Chopra I.J. The comparative effect of T4 and T3 on the TSH response in young adult males. J. Clin. Endocrinol. Metab. 44: 273, 1977.
Schimmel M., Utiger R.D. Thyroidal and peripheral production of thyroid hormones. Review of recent findings and their clinical implications. Ann. Intern. Med. 87: 760, 1977.
Krugman L.G., Hershman J.M. TRH test as an index of suppression compared with the thyroid radioiodine uptake in euthyroid goitrous patients treated with thyroxine. J. Clin. Endocrinol. Metab. 47: 78, 1978.
Johansen K., Hansen J., Perrild H., Skorsted L., Kampman J.P. The effect of suppressive therapy of nontoxic goiter on serum levels of thyroxine, 3,5,3′-triiodothyronine and 3, 3′, 5′-triiodothyronine. Acta Med. Scand. (Suppl.) 624: 25, 1979.
Lamberg B.-A., Rantanen M., Saarinen P., Liewendahl K., Sivula A. Suppression of TSH response to TRH by thyroxine therapy in differentiatedthyroid carcinoma patients. Acta Endocrinol. (Copenh.) 91: 248, 1979.
Ingbar J.C., Borges M., Iflah S., Kleinmann R.E., Braverman L.E., Ingbar S.H. Elevated serum thyroxine concentrations in patients receiving “replacement” dose of levothyroxine. J. Endocrinol. Invest. 5: 77, 1982.
Salmon D., Rendell M., Williams J., Smith C., Ross D.A., Wand J.M., Howard J.E. “Chemical hyperthyroidism”. Serum triiodothyronine levels in clinically euthyroid individuals treated with levothyroxine. Arch. Intern. Med. 142: 571, 1982.
Jennings P.E., O’Malley B.P., Griffin K.E., Northover B., Rosenthal F.D. Relevance of increased serum thyroxine concentrations associated with normal serum triiodothyronine values in hypothyroid patients receiving thyroxine: a case of “tissue thyrotoxicosis”. Br. Med. J. 289: 1645, 1984.
Pearce C.J., Himsworth R.L. Total and free thyroid hormone concentrations in patients receiving maintenance replacement therapy with thyroxine. Br. Med. J. 288: 693, 1984.
Pinchera A., Martino E., Pacchiarotti A., Bartalena L., Breccia M., Aghini-Lombardi F. Validity of serum free thyroid hormones in the assessment of the adequacy of L-thyroxine suppressive therapy. Nuc Compact 16: 387, 1985.
Rendell M., Salmon D. “Chemical hyperthyroidism”: the significance of elevated thyroxine levels in L-thyroxine treated individuals. Clin. Endocrinol. (Oxf.) 22: 693, 1985.
Bartalena L., Martino E., Pacchiarotti A., Grasso L., Aghini-Lombardi F., Buratti L., Bambini G., Breccia M., Pinchera A. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J. Clin. Endocrinol. Metab. 64: 849, 1987.
Same D.H., Refetoff S. Measurement of thyroxine uptake from serum by cultured human hepatocytes as an index of thyroid status: reduced thyroxine uptake from serum of patients with nonthyroidal illness. J. Clin. Endocrinol. Metab. 61: 1046, 1985.
Bartalena L., Tata J.R., Robbins J. Characterization of nascent and secreted thyroxine-binding globulin (TBG) in cultured human hepatoma (Hep G2) cells. J. Biol. Chem. 259: 13605, 1984.
Romelli P.B., Pennisi F., Vancheri L. Measurement of free thyroid hormones in serum by column adsorption chromatography and radioimmunoassay. J. Endocrinol. Invest. 2: 25, 1979.
Galen R.S., Gambino S.L. Beyond normality: the predictive value and efficiency of medical diagnoses. John Wiley & Sons, New York, 1980.
Pinchera A., Martino E., Bartalena L., Aghini-Lombardi F., Bambini G. Radioimmunoassay utilization in the assessment of thyroid status. In: Albertini A., Ekins R.P., Galen R.S. (Eds.), Cost/benefit and predictive value of radioimmunoassay. Elsevier, Amsterdam, 1984, p. 151.
Martino E., Bambini G., Bartalena L., Mammoli C., Aghini-Lombardi F., Baschieri L., Pinchera A. Human serum thyrotrophin measurement by ultrasensitive immunoradiometric assay as a first-line test in the evaluation of thyroid function. Clin. Endocrinol. (Oxf.) 24: 141, 1986.
Spencer C.A. Clinical evaluation of free T4 techniques. J. Endocrinol. Invest. 9 (Suppl. 4): 57, 1986.
Bartalena L., Mariotti S., Pinchera A. Radioimmunoassay of thyroid hormones. In: Patrono C., Peskar B.A. (Eds.), Handbook of Experimental Pharmacology. Springer-Verlag, Berlin, 1987, vol. 82, p. 401.
Bartalena L., Martino E., Falcone M., Buratti L., Grasso L., Mammoli C., Pacchiarotti A., Aghini-Lombardi F., Balzano S., Pinchera A. Evaluation of the nocturnal serum thyrotropin (TSH) surge, as assessed by TSH ultrasensitive assay, in patients receiving long term L-thyroxine suppression therapy and in patients with various thyroid disorders. J. Clin. Endocrinol. Metab. 65: 1265, 1987.
Spencer C.A., Lai-Rosenfeld A.O., Guttler R.B., Lo Presti J., Marcus A.O., Nimalasuriya A., Eigen A., Doss R.C., Green B.J., Nicoloff J.T. Thyrotropin secretion in thyrotoxic and thyroxine-treated patients: assessment by a sensitive immunoenzymometric assay. J. Clin. Endocrinol. Metab. 63: 349, 1986.
Ross D.S., Neer R.M., Ridgway E.C. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am. J. Med. 82: 1167, 1987.
Rosner W., Aden D.P., Khan M.S. Hormonal influences on the secretion of steroid-binding proteins by a human hepatoma-derived cell line. J. Clin. Endocrinol. Metab. 59: 806, 1984.
Olivo J., Southren A.L., Gordon G.G., Tochimoto S. Studies of the protein binding of testosterone in disorders of thyroid function. J. Clin. Endocrinol. Metab. 31: 539, 1970.
De Nayer Ph., Lambot M.P., Desmons M.C., Rennotte B., Malvaux P., Beckers C. Sex hormone-binding protein in hyperthyroxinemic patients: a discriminator for thyroid status in thyroid hormone resistance and familial dysalbuminemic hyperthyroxinemia. J. Clin. Endocrinol. Metab. 62: 1309, 1986.
Same D.H., Weinberg M. Normal cellular uptake of thyroxine (T4) from serum of patients with familial dysalbuminemic hyperthyroxinemia (FDH) or elevated thyroxine-binding globulin (TBG): T4 bound to albumin is not preferentially transferred to tissue. In: Medeiros-Neto G., Gaitan E. (Eds.), Frontiers in Thyroidology. Plenum Press, New York, 1986, vol. 1, p. 551.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bartalena, L., Martino, E., Falcone, M. et al. Thyroxine uptake by human hepatoma cells from serum of patients submitted to long-term thyroxine suppressive therapy. J Endocrinol Invest 11, 629–635 (1988). https://doi.org/10.1007/BF03350199
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350199